Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat disorders linked to dysfunctional signaling of the TGF-ß family of proteins.
President and CEO, Jasbir S. Seehra, Ph.D., will present at the Wells Fargo Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference.
Archived replays of the presentations will be accessible on the Keros website for up to 90 days after each event.
Focus on TGF-ß Proteins
Keros Therapeutics specializes in developing therapies targeting dysfunctional TGF-ß family proteins.
Product Candidates
KER-065 for neuromuscular diseases and elritercept for cytopenias are among Keros' leading product candidates.
Conference Participation
CEO Jasbir S. Seehra, Ph.D., will present at two upcoming healthcare conferences in September 2025.
- Keros Therapeutics aims to provide disease-modifying benefits to patients through novel protein therapeutics targeting TGF-ß proteins.
- The company's lead product candidate, KER-065, holds promise for treating neuromuscular diseases like Duchenne muscular dystrophy.
Keros Therapeutics' focus on therapeutic development for disorders related to TGF-ß family proteins marks it as a key player in the biopharmaceutical industry.